Clinical Efficacy of CAG Regimen Combined with Venetoclax, Chidamide, and Azacitidine in the Treatment of Elderly Patients with Acute Myeloid Leukemia.
Clinical trial shows significant efficacy and safety of CAG regimen combined with venetoclax and chidamide for elderly AML patients, indicating promising treatment options.
Key Points
The overall response rate was 93.3%, with 11 out of 15 patients achieving complete response after treatment.
A follow-up analysis showed that all patients with detectable gene mutations achieved a composite response, supporting the treatment's efficacy.
The average recovery time for white blood cell count was 14.6 days post-chemotherapy, indicating effective patient monitoring.
Myelosuppression was the main adverse event, but serious complications were minimal during the treatment process.